Gabriela Lofland
YOU?
Author Swipe
View article: Supplementary Figure S4 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S4 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Evaluation of [68Ga]Ga-DK223 in genetically hPD-L1 overexpressing model.
View article: Supplementary Figure S5 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S5 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Evaluation of [68Ga]Ga-DK223 ability to detect inducible PD-L1.
View article: Supplementary Figure S6 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S6 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
[68Ga]Ga-DK223 PET reveals differential activity of PD-L1 antibodies over time in BFTC909 xenografts.
View article: EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment
EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment Open
Background: Pancreatic ductal adenocarcinoma (PDAC) presents a formidable challenge in oncology due to its aggressive nature and resistance to therapy. Current treatments, including surgery, chemotherapy, and radiotherapy, have limi…
View article: Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation
Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation Open
In this study, we synthesized a multimodal theranostic agent capable of delivering DM1 and a radionuclide to PSMA+ tumors. This approach holds promise for enhancing image-guided treatment of aggressive, metastatic subtypes of pr…
View article: CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET
CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET Open
The limited availability of molecularly targeted low‐molecular‐weight imaging agents for monitoring multiple myeloma (MM)‐targeted therapies has been a significant challenge in the field. In response, a first‐in‐class peptide‐based radiotr…
View article: Non-invasive PD-L1 quantification using [<sup>18</sup>F]DK222-PET imaging in cancer immunotherapy
Non-invasive PD-L1 quantification using [<sup>18</sup>F]DK222-PET imaging in cancer immunotherapy Open
Background Combination therapies that aim to improve the clinical efficacy to immune checkpoint inhibitors have led to the need for non-invasive and early pharmacodynamic biomarkers. Positron emission tomography (PET) is a promising non-in…
View article: Preclinical Evaluation of a New Series of Albumin-Binding 177Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics
Preclinical Evaluation of a New Series of Albumin-Binding 177Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics Open
Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with metastatic castration-resistant prostate cancer. Although result…
View article: A Gallium-68-Labeled Peptide Radiotracer For CD38-Targeted Imaging In Multiple Myeloma With PET
A Gallium-68-Labeled Peptide Radiotracer For CD38-Targeted Imaging In Multiple Myeloma With PET Open
Purpose The limited availability of molecularly targeted low-molecular-weight imaging agents for monitoring multiple myeloma (MM)-targeted therapies has been a significant challenge in the field. In response, we developed [ 68 Ga]Ga-AJ206,…
View article: Supplementary Figure S5 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S5 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Evaluation of [68Ga]Ga-DK223 ability to detect inducible PD-L1.
View article: Supplementary Figure S3 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S3 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
A, Comparison of hPD-L1 surface expression in different cancer cell lines with respective isotype.
View article: Supplementary Figure S6 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S6 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
[68Ga]Ga-DK223 PET reveals differential activity of PD-L1 antibodies over time in BFTC909 xenografts.
View article: Supplementary Figure S2 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S2 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
A, Comparison of DOTA and DOTAGA analogs of DK221.
View article: Supplementary Figure S5 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S5 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Evaluation of [68Ga]Ga-DK223 ability to detect inducible PD-L1.
View article: Supplementary Figure S2 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S2 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
A, Comparison of DOTA and DOTAGA analogs of DK221.
View article: Supplementary Figure S3 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S3 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
A, Comparison of hPD-L1 surface expression in different cancer cell lines with respective isotype.
View article: Supplementary Figure S4 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S4 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Evaluation of [68Ga]Ga-DK223 in genetically hPD-L1 overexpressing model.
View article: Supplementary Figure S4 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S4 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Evaluation of [68Ga]Ga-DK223 in genetically hPD-L1 overexpressing model.
View article: Data from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Data from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Purpose:Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients. Tumor drug exposure measurements can provide vital insights into mechanisms involved in the resistance of solid tumors to those therapeutics; howev…
View article: Supplementary Figure S6 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S6 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
[68Ga]Ga-DK223 PET reveals differential activity of PD-L1 antibodies over time in BFTC909 xenografts.
View article: Supplementary Figure S1 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S1 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
A, Synthesis of DK223. B, RP-HPLC chromatogram of DK223.
View article: Supplementary Figure S7 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S7 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Ex vivo biodistribution of [68Ga]Ga-DK223 in mice bearing BFTC909 xenografts and treated with aPD-L1 antibodies for 120 h.
View article: Supplementary Figure S7 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S7 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Ex vivo biodistribution of [68Ga]Ga-DK223 in mice bearing BFTC909 xenografts and treated with aPD-L1 antibodies for 120 h.
View article: Supplementary Figure S1 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Supplementary Figure S1 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
A, Synthesis of DK223. B, RP-HPLC chromatogram of DK223.
View article: Data from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Data from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Purpose:Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients. Tumor drug exposure measurements can provide vital insights into mechanisms involved in the resistance of solid tumors to those therapeutics; howev…
View article: Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Open
Purpose: Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients. Tumor drug exposure measurements can provide vital insights into mechanisms involved in the resistance of solid tumors to those therapeutics; howe…